T memory stem (T SCM ) cells are a rare subset of memory lymphocytes endowed with the stem cell-like ability to self-renew and the multipotent capacity to reconstitute the entire spectrum of memory and effector T cell subsets. Cumulative evidence in mice, nonhuman primates and humans indicates that T SCM cells are minimally differentiated cells at the apex of the hierarchical system of memory T lymphocytes. Here we describe emerging findings demonstrating that T SCM cells, owing to their extreme longevity and robust potential for immune reconstitution, are central players in many physiological and pathological human processes. We also discuss how T SCM cell stemness could be leveraged therapeutically to enhance the efficacy of vaccines and adoptive T cell therapies for cancer and infectious diseases or, conversely, how it could be disrupted to treat T SCM cell driven and sustained diseases, such as autoimmunity, adult T cell leukemia and HIV-1.
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-Thucydides, The History of the Peloponnesian War (translation by Thomas Hobbes)
Immunological memory-the ability to remember and respond rapidly and more vigorously to a pathogen upon subsequent encounters-has long been recognized in human history. The first documentation of immunological memory came from the Greek historian Thucydides, who vividly described the plague that struck the city of Athens in 430 bc, recounting that "this disease never took any man the second time" 1 . It took us more than two millennia to understand that immunological memory is a fundamental property of the adaptive immunity conveyed by B and T lymphocytes 2 . Despite the enormous progress in our understanding of basic aspects of T cell immunity, the ontogeny of memory T cells remains a matter of active debate 3, 4 . It is clear, however, that immunological memory and protective immunity can last several decades and perhaps a lifetime, even in the absence of re-exposure to the pathogen 5, 6 . This astonishing stability of T cell memory, despite the high cellular turnover that characterizes immune responses and the lack of replenishment of antigen-specific T cells from hematopoietic stem cells (HSCs)-owing to constraints imposed by stochastic recombination of the T cell receptor (TCR) and thymic involution-has sparked the idea that T cell immunity could be maintained via stem cell-like memory T cells 7 . Over the past decade, the realization that memory T cells share a core transcriptional signature with HSCs 8 and display functional properties found in stem cells, such as the capacity to divide asymmetrically to generate cellular heterogeneity 9 , has further strengthened the view that T cells, akin to all somatic tissues, might be organized hierarchically and sustained by antigen-specific T memory stem cells 10 .
In this Review, we outline emerging findings demonstrating that a subset of minimally differentiated memory T cells behave as antigenspecific adult stem cells. We also discuss recent evidence placing these T SCM cells at center stage in many physiological and pathological human processes. Finally, we highlight ongoing efforts aimed at either harnessing the therapeutic potential of T SCM cells for adoptive immunotherapies or, conversely, at destabilizing the T SCM cell compartment to eliminate drug-resistant viral reservoirs or treat adult T cell leukemia and autoimmune diseases. The conceptual work and key discoveries that have shaped this field of investigation are summarized in Figure 1 .
The discovery of T SCM cells
Advances in multiparameter flow cytometry over the past 20 years have enabled dissection of the heterogeneity of the T cell compartment with ever-increasing precision 11 . In a seminal study, van Lier and colleagues identified human naive, memory and effector T cell subsets on the basis of the combinatorial expression of CD27 and CD45RA, with naive cells expressing both molecules, and memory and effector cells expressing only CD27 or CD45RA, respectively 12 . Subsequent work by Sallusto et al. 13 revealed the presence of two major functional subsets within the CD45RA − memory T cell pool: central memory T (T CM ) cells, which express the lymph node homing molecules CCR7 and CD62L and have limited effector functions, and CCR7 − CD62L − effector memory T (T EM ) cells, which preferentially traffic to peripheral tissues and mediate rapid effector functions.
The idea that memory T cells might not be confined solely to the CD45RA − T cell compartment, but might also be present within what was considered to be a naive T cell population, began to take shape following the identification in mice of a memory T cell population that is characterized by a naive-like phenotype, but that expresses high amounts of stem cell antigen 1 (SCA1) and the memory markers interleukin-2 receptor β (IL-2Rβ) and chemokine C-X-C motif receptor 3 (CXCR3) 14 . These cells were termed T SCM cells because it was observed that they were capable of sustaining graft-versus-host disease (GVHD) upon serial transplantation into allogeneic hosts, and that they could reconstitute the full diversity of memory and effector T cell subsets while maintaining their own pool size through self-renewal 14 .
Identifying the human counterpart of T SCM cells, however, has not been straightforward, mainly owing to the lack of a human ortholog of SCA1, the prototypical marker of mouse T SCM cells. Although it was known that a substantial fraction of long-lived antigen-specific CD8 + and CD4 + memory T cells displayed a naive-like phenotype (CD45RA + CCR7 + CD27 + ) years after infection with EBV 15 or vaccination with attenuated smallpox or yellow fever (YF) viruses 16, 17 , a precise set of surface markers with which to pinpoint this elusive memory phenotype in humans was missing. The breakthrough came with the demonstration that mouse T SCM cells could be generated successfully in vitro from naive precursors by activating the Wnt-β-catenin signaling pathway using the Wnt ligand, Wnt3a or inhibitors of glycogen synthase kinase-3β (ref. 18) . By using this strategy to characterize extensively the phenotype of candidate human T SCM cells generated in vitro, it was possible to identify key surface markers that can distinguish naturally occurring human T SCM cells from the naive T cell pool 19 . Similar to their mouse counterparts, human and nonhuman primate (NHP) T SCM cells are clonally expanded cells that express a largely naive-like phenotype in conjunction with a core of memory markers, such as CD95, CXCR3, IL-2Rβ, CD58 and CD11a 19, 20 . These cells represent a small fraction of circulating T lymphocytes (≈2-3%). Notably, the frequency of circulating T SCM cells does not vary substantially with age 21 , but it seems to be heritable and associated with single-nucleotide polymorphisms (SNPs) at a genetic locus containing CD95 (ref. 22 ), which suggests a potential role of FAS signaling in the regulation of T SCM cell homeostasis. T SCM cells exhibit all the defining properties of memory cells, including a diluted content of TCR excision circles, the ability to proliferate rapidly and release inflammatory cytokines in response to antigen re-exposure, and a dependence on IL-15 and IL-7 for homeostatic turnover 19, 23 . Despite being functionally distinct from naive T cells, T SCM cells share with them similar recirculation patterns and distribution in vivo, as evidenced by detailed compartmentalization studies in NHPs 24 . For instance, T SCM cells are found more abundantly in lymph nodes than in the spleen and bone marrow, and they are virtually absent from peripheral mucosae 24 . Thus, T SCM cells represent a subset of minimally differentiated T cells characterized by phenotypic and functional properties that bridge naive and conventional memory cells (Fig. 2) .
T SCM cells: evidence of stemness
The concept of stemness embraces the capacity both to self-renew and to generate the entire spectrum of more differentiated cells 25 . When Fearon and colleagues 7 initially postulated the existence of a stem cell pool of memory T lymphocytes, the authors pointed to T CM cells 27, 28 . By contrast, T EM cells were unable to serially reconstitute the host, even when transferred at 100-fold higher numbers, and so showed a limited capacity for self-renewal. Although these experiments did not evaluate T SCM cells, these results, when combined with those of sophisticated experiments tracking T cell fates in mice through genetic barcoding 29 and on single naive T cell transfer 30 , provided strong support for the progressive model of T cell differentiation originally developed by Sallusto and Lanzavecchia 31 . Indeed, three separate models have been proposed to explain memory T cell differentiation 3 : according to the first two models, memory T cells originate from effectors either after 26 or before 32 the peak of T cell expansion. The progressive differentiation model, on the contrary, suggests that memory T cells are derived directly from naive lymphocytes upon priming, and further differentiate into shorter-lived effector subsets in a hierarchical differentiation tree, similarly to that of other organ systems 31 ( Fig. 2) . By using hematopoietic stem cell transplantation (HSCT) from haploidentical donors as a model system to study T cell differentiation, two independent groups have shown recently at polyclonal, antigen-specific and clonal levels that human T SCM cells differentiate directly from naive precursors and emerge early upon in vivo priming 33, 34 . By multiparametric flow cytometry and TCR sequencing, it was possible to trace and quantify the in vivo differentiation landscapes of transferred naive T cells, which showed that more than 30% of naive T cells undergoing priming differentiate into T SCM cells 33, 34 . Indeed, discrete T cell subsets traced across HSCT behaved preferentially within a progressive framework of differentiation. Notably, only naive T cells and T SCM cells were able to reconstitute the entire heterogeneity of memory T cell subsets, including T SCM cells 33 . A fraction of cells originally designated as T EM cells reverted to a T CM cell phenotype 33 . By contrast, only a very limited number of T CM and T EM cells converted to the T SCM cell type 33 . Echoing these findings, the transfer of genetically modified virus-specific T cells reconstituted the full diversity of the T cell memory compartmentinclusive of T SCM , T CM and T EM cells-only when T SCM cells were present within the infused cell product 35 . All together, these results strengthen earlier in vitro observations in humans 19 and NHPs 24 showing that the potential to form diverse progeny is progressively restricted as the cell type proceeds from T SCM to T CM and T EM cells. Thus, granting some level of plasticity to the system, these data point to a progressive model of T cell differentiation, in which T SCM cells are at the apex of the hierarchical tree. In line with this concept, the gene expression profile of human T cell subsets partitions T SCM cells with antigen-experienced T cells and places them at a hierarchically superior level over the T CM cell type 19, 23, 36, 37 . The concept of stemness also involves self-renewal and implicates long-term persistence 25 . The long-term persisting ability of T SCM and other antigen-experienced T cells cannot be addressed easily in humans because naive T cells are generated continuously, and several antigenic contacts might occur after the initial encounter. Longitudinal monitoring of genetically engineered lymphocytes infused as antigen-experienced cells, and distinguishable from endogenous lymphocytes thanks to the retroviral integration and transgene expression, has recently enabled the tracking of single T cell clonotypes over time. In patients afflicted with the adenosine deaminase (ADA)-deficient form of severe combined immunodeficiency (SCID), genetically engineered T SCM cells persisted and preserved their precursor potential for decades 38 . Engineered lymphocytes were tracked for up to 14 years in patients with leukemia who were treated with haploidentical HSCT and donor lymphocytes transduced retrovirally to express a suicide gene 35 . This study revealed that the extent of expansion and the amount of persisting genemarked T cells are tightly correlated with the number of T SCM cells infused, which indicates that this subset of memory cells is endowed with enhanced proliferative potential, immune-reconstitution capacity and longevity 35 . Notably, the same observation has been reported in a clinical trial based on the infusion of autologous T cells that have been genetically engineered to express a chimeric antigen receptor (CAR) 39 , which underscores that this phenomenon is not confined to the HSCT model. In patients treated with suicide-gene therapy, it was possible to detect circulating gene-modified T cells from 2 to 14 years after treatment. Viral integration and TCR-α and TCR-β clonal markers were used to trace longitudinally single, genemodified T cell clones, sorted according to the T cell differentiation phenotype in the infused products and in patients, at long-term follow-up. It was thus possible to show that dominant T cell clones detected long term originate preferentially from infused T SCM cells, and to a lesser degree, from T CM clones 35 . Taken together, these results indicate that human T SCM cells have an exceptional capacity to persist long term. Similar conclusions were reached by monitoring T cell subset dynamics in NHP models of infection 24 and patients with HIV-1 undergoing antiretroviral therapy (ART) 40 ; two experimental settings in which antigen load and time of antigen exposure can be controlled precisely. By taking advantage of the peculiar biology of the Tat-specific epitope TL8, which uniformly undergoes escape mutation within 4-5 weeks after infection with simian immunodeficiency virus (SIV), Lugli et al. 24 investigated the persistence of different memory Tat-specific T cell subsets in the virtual absence of any stimulation with antigen. In this setting, T SCM cells were able to persist at unchanged levels for up to 70 d after infection, whereas T CM and T EM cells contracted tenfold and 100-fold, respectively 24 . Similarly, pharmacological antigen withdrawal in ART-treated patients with HIV-1 was associated with a decline of HIV-1-specific T EM cells and terminally differentiated effector (T TE ) cells, whereas the T SCM cell type gradually increased in number under these conditions 40 .
Mirroring these findings, after YF vaccination virus-specific T TE cells underwent a more pronounced contraction than T EM cells, which in turn declined more steeply than T CM cells 36 . Remarkably, the frequency of YF-specific T SCM cells was maintained stably even 25 years after vaccination 36 . Taken together, this series of studies provides compelling evidence that human T SCM cells are generated directly from naive lymphocytes and are endowed with long-term self-renewal capacity and multipotency.
T SCM cells in host defense
Pathogen-specific T SCM cells have been increasingly identified in human acute and chronic infections caused by viruses, bacteria and parasites 19, 35, 36, [40] [41] [42] . These results demonstrate that T SCM cells are commonly generated during natural immune responses against foreign pathogens, but the underlying mechanisms remain poorly understood. Human studies are limited in that the exact time of infection is usually unknown, which makes it difficult to study T cell priming and kinetics. By contrast, active vaccination offers the possibility of inducing an immune response in a supervised fashion. Smallpox and YF vaccines are particularly suitable models of human primary acute viral infection because they consist of live, attenuated, replicationcompetent viruses capable of inducing strong immune responses with consequent clinical symptoms 43 . By using YF vaccination as a model system, the kinetics of T SCM cell formation and long-term maintenance have recently been studied in great detail 36 . Consistent with findings from studies of SIV infection in NHPs 24 , YF-specific T SCM cells were detectable at early time points after vaccination when the immune response was dominated by effector T cells 36 . These T SCM cells persisted at stable levels and became the major YF-specific memory T cell population in the circulation decades after the initial immunization 36 . Considering that YF vaccination provides life-long protection 43 , it is reasonable to assume that T SCM cells have a central role in the maintenance of long-term T-cell memory. The presence of a relevant pool of T SCM cells might also be essential for the control of persisting infections, in which effector T cells undergoing functional exhaustion and replicative senescence need to be replenished continuously by less differentiated T cell subsets [44] [45] [46] [47] . Notably, recent studies in chronic viral 40, 48 and parasitic infections 42 revealed a negative correlation between the severity of disease and the frequency of circulating T SCM cells. It is unclear whether these observations result from the inability of T SCM cells to be maintained under conditions of strong inflammation and high antigenic load, or vice versa, that the presence of insufficient numbers of T SCM cells impairs the ability of the immune system to control pathogen replication. However, emerging findings suggest that T SCM cells are crucial to the maintenance of immune homeostasis; high levels of infection of the T SCM cell compartment and its subsequent functional perturbation have been linked to the development of symptomatic immune deficiency following SIV and HIV-1 infections 49, 50 . Indeed, high quantities of SIV DNA were found in CD4 + T SCM cells from rhesus macaques, who typically develop an AIDS-like clinical picture when left untreated, but they were not found in CD4 + T SCM cells from SIV-infected sooty mangabeys, a group of NHPs that are refractory to clinical or laboratory signs of immune deficiency even when high levels of virus circulate in the peripheral blood 49, 51, 52 . Resonating with this observation, viremic nonprogressors-a rare group of untreated patients with HIV-1 who develop high levels of HIV-1 replication in the absence of clinical immune deficiency-exhibit reduced levels of HIV-1 DNA in CD4 + T SCM cells in comparison to patients with HIV-1 who show ordinary rates of disease progression 50 . All together, these results underscore a crucial function of T SCM cells in the sustenance of long-lasting cellular immunity against acute and chronic microbial infections.
Given the pivotal role of T SCM cells in the maintenance of life-long immunological memory, it would be desirable to develop vaccines that are capable of inducing substantial numbers of T SCM cells. The majority of clinical vaccine formulations designed to stimulate CD8 + T cellmediated immunity induce predominantly T EM , and few memory, cells 53, 54 . These vaccines are rarely efficacious as compared to those that induce protective antibodies 2, 55 . Indeed, current T cell vaccines seem inefficient at triggering mechanisms that are key for the development of memory T cells, including optimal signaling via the TCR and the induction of appropriate metabolic programs, transcription factors and chromatin reorganization 56 . Considering that the activation of CD8 + T cells under conditions of low-level inflammation enhances memory cell formation, one might surmise that vaccines should, ideally, stimulate T cells without triggering the excessive release of proinflammatory cytokines 57 . It is, however, debatable whether optimal generation of memory T cells requires the avoidance of effector cell differentiation. This is illustrated by the fact that natural infections generate sound memory T cell responses, including T SCM cells, despite the initial predominance of effector cells 43 . Indeed, the emergence of T SCM cells was recently observed after the administration of a subunit cancer vaccine capable of inducing a rapid and robust expansion of effector T cells 58 . Much work remains to be done in this area; however, the induction of T SCM cells by novel vaccines should not be at the expense of more differentiated T EM and tissue-resident memory cells, which assure immediate protection at the entry site of re-infection in peripheral tissues [59] [60] [61] . Ideally, new vaccines will be able to recreate the full spectrum of memory cell phenotypes that human pathogens and their pathophysiological properties induce in vivo 62, 63 .
T SCM cells can exacerbate human disease
The complex biology of T SCM cells can make it difficult to discriminate between their protective and pathogenic effects because the very characteristics that enable T SCM cells to represent the backbone of life-long cellular immunity under physiologic conditions might empower these cells to drive disease pathogenesis 64 . This seems particularly relevant in the setting of a growing list of immune-mediated diseases associated with aberrant and autoreactive memory T cells. For instance, recent correlative studies have suggested an increased frequency and activation state of CD8 + T SCM cells in individuals with aplastic anemia, a disease mediated by autoreactive cytotoxic T cells targeting hematopoietic progenitors, as compared to healthy individuals 65 .
Moreover, an elevated number of CD8 + T SCM cells after immunosuppressive treatment was associated with treatment failure and subsequent aplastic anemia relapse 65 . Elevated numbers of T SCM cells were also noted in patients with uveitis, but not in those with systemic lupus erythematosus, an immune-mediated disease characterized primarily by autoreactive humoral responses 65 . Further pointing toward a role of T SCM cells in the pathogenesis of autoimmune diseases and other illnesses of the lymphatic system, a recent genomewide association study found a strong association between genetic polymorphisms affecting susceptibility to juvenile idiopathic arthritis or chronic lymphocytic leukemia, and the frequency of CD4 + T SCM cells 22 . How T SCM cells can influence autoimmune diseases will have to be studied in dedicated investigations, but on the basis of current knowledge, it is reasonable to hypothesize that long-lasting autoreactive or abnormally activated T SCM cells might induce self-renewing inflammatory cellular responses that are responsible for the durable, and in most cases life-long, persistence of such diseases 66 . The possible role of T SCM cells in other diseases with profound disturbance of cellular immune responses, such as autoimmune hepatitis, thyroiditis, type 1 diabetes and certain types of glomerulonephritis, are currently unknown but represent a high priority area of future research.
In addition to their role in autoimmunity, T SCM cells might have a distinct role in viral diseases in which T cells represent the predominant targets, such as infections caused by CD4 + T cell tropic retroviruses. Notably, work in the context of HIV-1 infection has shown that CD4 + T SCM cells can effectively support both productive viral replication and a transcriptionally silent form of infection 67 . Moreover, by infecting long-lived CD4 + T SCM cells, HIV-1 is able to exploit their stemness to establish an extremely durable, self-renewing viral reservoir that can persist for decades, despite ART, and continuously replenish virally infected cells, thus perpetuating a disease that they are meant to restrict 68 . Indeed, the half-life of HIV-1-infected T SCM cells in ART-treated individuals has been estimated to be around 277 months, a time period substantially longer than that observed for viral reservoirs established in more short-lived T cell populations 69 . In line with these observations, phylogenetic studies demonstrated close associations between viruses circulating early after HIV-1 infection and viral sequences isolated from CD4 + T SCM cells after almost a decade of suppressive ART 68 . Notably, the ability to use CD4 + T SCM as a long-term viral reservoir also seems to occur in individuals infected with HTLV-1, a retrovirus related to HIV-1 that is the primary cause of adult T cell leukemia (ATL). Emerging data indicate that transformed, HTLV-1 infected CD4 + T SCM cells can act as progenitors for dominant circulating ATL clones and can efficiently propagate ATL upon transplantation in animal models 70 . This suggests that they can serve as a cancer stem cell population responsible for the propagation and maintenance of HTLV-1-infected malignant cells.
Targeting T SCM cells for therapy Harnessing T SCM cells for adoptive T cell therapy.
The extreme longevity, the robust proliferative potential and the capacity to reconstitute a wide-ranging diversity of the T cell compartment make the T SCM cell type an ideal cell population to employ in adoptive immunotherapy (Fig. 3) . Driven by the growing success of clinical trials that are based on the transfer of naturally occurring and genetically engineered tumor-reactive T lymphocytes, adoptive immunotherapies are rapidly becoming a real therapeutic option for patients with cancer 71, 72 . Although these regimens can induce complete and durable tumor regressions in patients with advanced cancer, current response rates remain mostly inadequate, which underscores the need for further improvements 71, 72 . There is now extensive evidence indicating that objective responses are strongly correlated with the level of T cell engraftment and peak of expansion early after transfer [73] [74] [75] [76] [77] [78] [79] . T cell persistence, although not strictly indispensable in certain conditions [74] [75] [76] [77] 80 , has also been associated with the likelihood of objective responses in numerous trials 78, 79, [81] [82] [83] [84] [85] and might be required to sustain durable remissions 86 . These parameters are influenced considerably by the composition of the infused T cell product because T cell subsets differ widely in terms of proliferative capacity, immune reconstitution and long-term survival 10, 87 . Indeed, the administration of cells with longer telomeres 83, 88 or cell products comprising higher fractions of CD62L + , CD28 + or CD27 + T cells has been shown to correlate with objective tumor responses in patients 83, [88] [89] [90] , which suggests that less differentiated T cells are therapeutically superior to T TE cells. Notably, the engraftment and expansion of T cells engineered to express a CD19-specific CAR 39 or a suicide gene 35 was correlated with the frequency of infused CD8 + CD45RA + CCR7 + T SCM cells. Adoptive transfer experiments in mice, using defined T cell subsets, have demonstrated formally that the infusion of less-differentiated CD62L + T cell populations results in enhanced T cell engraftment, expansion and persistence, which leads ultimately to more profound and durable tumor regressions 18, 19, [91] [92] [93] [94] [95] . Consistent with the developmental hierarchy, minimally differentiated T SCM cells mediate more potent antitumor responses than T CM cells, which, in turn, are more effective than highly differentiated T EM cells 18, 19, 96 . Some level of plasticity, however, must be granted to the hierarchical model of memory T cell differentiation. In NHPs, genetically engineered CMV-specific effectors derived from purified T CM cells proved superior to effectors derived from T EM cells in terms of expansion and persistence in vivo, which shows that even after manipulation in vitro and, apparently, a similar degree of terminal differentiation, T cells maintain some characteristics of the subset of origin, and can possibly, at least in part, revert to that original phenotype and function 97 . Despite overwhelming preclinical data indicating a therapeutic advantage to transferring tumor-reactive CD62L + T cell subsets 18, 19, [91] [92] [93] [94] [95] , clinical trials have largely employed unselected intratumoral or peripheral blood mononuclear cell (PBMC)-derived T cell populations. Tumor-infiltrating lymphocytes are typically in a state of terminal differentiation and functional exhaustion, which makes the isolation of early memory T cell subsets impractical 98, 99 . However, the selection of less differentiated T cell subsets becomes realistic and desirable in the context of immunotherapies that are aimed at conferring tumor reactivity to circulating T cells via TCR or CAR gene engineering. The isolation of less differentiated T cell populations also has the advantage of reproducibly generating more defined T cell products. Indeed, PBMC composition can vary substantially between individuals as a consequence of age 100 , pathogen exposure 101 and prior systemic treatments 102 . Moreover, unselected populations containing high proportions of T EM and effector cells might fail to generate viable clinical products owing to poor in vitro cell expansion 103 . Recently, a few clinical trials in which CD19-specific CAR T cells were generated from isolated T CM cells have been reported 86, 104, 105 . This strategy led to the generation of infusion products composed of substantially more T EM cells than those originating from unselected PBMCs, which indicates that, in the absence of culture conditions restraining T cell differentiation 18, [106] [107] [108] [109] [110] , the benefit of depleting highly differentiated T cell subsets is outweighed by the concomitant removal of naive and T SCM cells 104 . Notwithstanding the reduction of less differentiated T cell subsets, the rates of objective remissions in patients with acute lymphoblastic leukemia (ALL) were comparable to results of trials that used unselected T cell populations 74, 75, 78, 104, 111, 112 . Whether differences in manufacturing and T cell product composition will affect the rates and duration of clinical responses in other diseases and settings remains to be shown.
So far, the clinical exploitation of T SCM cells has been hindered by their relative paucity in the circulation 19, 20 and the lack-until recently-of robust, clinical-grade manufacturing protocols that are capable of generating and maintaining this cell type in vitro. These strategies rely on programming and redirecting T SCM cells from naivelike T cells isolated from PBMCs 23, 113 (Fig. 3) . Although the isolation of naive T cells adds complexity to the manufacturing process, it is a crucial step because the presence of more differentiated T cell subsets during naive T cell stimulation accelerates naive T cell differentiation into T EM and T TE cells 114 . It should also be considered that purifying large numbers of specific cell subsets over multiple parameters under good manufacturing practice conditions is becoming increasingly accessible thanks to recent developments in clinical cell-sorting technologies 87, 115 . IL-7 and IL-15 have been used successfully to generate tumor-redirected or suicide-gene-modified T SCM cells from naive cell precursors 23 (Fig. 3) . IL-7 is essential for the development of these cells 23, 116 , whereas IL-15 primarily sustains their expansion 23 . IL-7 and IL-15-programmed T SCM cells possess a core gene signature of naturally occurring T SCM cells, display an enhanced proliferative capacity as compared to other T cell subsets and are uniquely capable of expanding and mediating GVHD upon serial transplantation 23 . This cytokine combination could also be employed to generate large numbers of TCR-gene-edited T SCM cells by combining zinc-finger nuclease sets specific for the endogenous TCR gene loci with viral vectors encoding tumor-specific TCRs 117 (Fig. 3) . Moreover, the ability of IL-7 and IL-15 to support the formation and expansion of T SCM cells makes it an ideal strategy for generating T SCM cells without the need to redirect their specificity. This might be particularly suitable for the generation of virus-specific T SCM cells for the treatment and prevention of life-threatening infections after transplantation (Fig. 3) , given that infection control can be obtained by transferring relatively small numbers of virus-specific memory cells 118 . A demonstration that IL-7 and IL-15 could be employed successfully to generate and expand virus-specific T SCM cells, starting from isolated naive-like cells, was provided recently by Volk and colleagues 119 . This protocol could also be adapted to generate CARmodified virus-specific T SCM cells, which might lower the risk of GVHD, given the restricted TCR repertoire, and which may exhibit additional proliferative and survival advantages as a result of the triggering in vivo of the native virus-specific TCRs by antigens frompersistent viruses 82, 120 . Another clinical-grade strategy promoting the generation of tumor-reactive T SCM cells is based on the activation of naive-like lymphocytes in the presence of IL-7, IL-21 and the Wnt agonist TWS119 (ref. 113) . Although both 122) and have been implicated in the generation and maintenance of memory T cells, IL-21 is more effective in restraining T cell differentiation 107 , owing to its specific ability to activate signal transducer and activator of transcription 3 (STAT3) signaling 126 and to sustain the expression of the Wnt-β-catenin transcription factors TCF7 and LEF1 (ref. 107 ). TWS119 has a synergistic effect with IL-21 to induce maximal expression of TCF7 and LEF1 by stabilizing β-catenin 113 . CAR-modified T SCM cells generated under these culture conditions are phenotypically, functionally and transcriptionally equivalent to their naturally occurring counterparts 113 . Moreover, they exhibit metabolic features, such as a high spare respiratory capacity 127 and low glycolytic metabolism 128 , that are characteristic of long-lived memory T cells. Although these culture conditions profoundly inhibit T cell proliferation, T SCM cells can be redirected efficiently against a tumor antigen and expanded to clinically relevant numbers 113 . More importantly, CAR-modified CD8 + T SCM cells mediated superior and more durable anti-tumor responses than cells generated with protocols currently employed in clinical trials 113 . CAR-modified T SCM cells might also provide an attractive approach for immunotherapy in the setting of nonmalignant diseases, such as HIV-1 infection or other chronic viral illnesses 129, 130 (Fig. 3) . All together, these studies provide both a strong scientific rationale and practical methodologies for the rapid advancement of T SCM cells in human clinical trials of adoptive immunotherapy 131 .
Disrupting T SCM cell reservoirs in retroviral infections and autoimmune diseases. The emerging role of CD4 + T SCM cells in the pathogenesis of chronic viral infections such as HIV-1 and HTLV-1 infection might also offer novel opportunities to prevent, treat or cure these diseases. In the context of HIV-1 infection, specific interventions that eliminate HIV-1-infected CD4 + T SCM cells might allow for the destabilization of HIV-1 reservoirs by reducing the number of HIV-1-infected source cells from which new HIV-1 + viral and cellular progeny can continuously originate, despite suppressive ART. As the molecular programs that govern the stem cell-like behavior of T SCM cells continue to be understood, new molecules regulating proliferation and selfrenewal of T SCM cells might represent attractive targets for reducing viral persistence in CD4 + T SCM cells. For instance, Wnt-β-catenin signaling has been identified as a key driver for the homeostasis of T SCM cells 18 , and pharmaceutical inhibition of this pathway might therefore translate into a more limited ability of HIV-1 to use the T SCM compartment for maintaining the survival of virally infected cells (Fig. 3) . This approach might be facilitated by the availability
Box 1 T SCM cell biology: outstanding questions
Several questions regarding T SCM cell biology remain unresolved. A major issue is how T SCM cells form during infection. Is T SCM cell fate programmed at the time of naive T cell priming, or is it shaped throughout multiple antigen encounters and the diverse inflammatory environments that their progeny experience? A glimpse into T SCM cell transcriptional and epigenetic landscapes 19, 36, 37, 137, 138 and metabolism 113, 137 has begun to reveal the molecular and metabolic programs of T SCM cells. Whether asymmetric partitioning of key transcription factors 139, 140 and metabolic master regulators 141, 142 is programming T SCM cell formation is unknown. Additionally, T SCM cell anatomical niches remain elusive. Progress has been hampered by the rarity of T SCM cells, which limits epigenetic, proteomic and metabolomic studies. The lack of mouse models of infection that are capable of generating robust numbers of T SCM cells has precluded researchers from evaluating specific gene contributions to T SCM cell physiology with genetic tools, and from imaging T SCM cell dynamics within tissues by real-time microscopy.
T SCM cell epigenetic and transcriptional programs. Transcriptomic analyses of whole 19, 137 and YF-specific T SCM cells 36, 37 have revealed that this cell type is closely related to T CM cells. These findings suggest that the majority of transcriptional pathways shaping T CM cell development and maintenance might also regulate T SCM cells. For instance, Wnt-β-catenin signaling is essential for T CM cell formation and survival [143] [144] [145] [146] , but is also crucial for the generation of T SCM cells 18, 19, 113 . Likewise, tempering mTOR signaling enhances the development of both T CM 147, 148 and T SCM cells 137 . Whether specific transcriptional networks are uniquely activated to influence T SCM cell fate is unknown. It is also unclear what role CD95-FAS ligand signaling in T SCM cell homeostasis has. Overlying the transcriptome is the undefined T SCM cell epigenetic program. Genome-wide analysis of histone methylation in naive and in vitro-generated mouse CD8 + T cell subsets, including T SCM cells, have revealed that chromatin accessibility is mostly regulated in a progressive fashion 138 , but that confirmation in ex vivo-isolated cells is warranted.
T SCM cell metabolism. Metabolism is intimately linked to T cell activity and fate 149 . Fatty acid oxidation, increased mitochondrial biomass and spare respiratory capacity support the development and function of memory T cells 127, 150 . Conversely, aerobic glycolysis favors terminal-effector differentiation, limiting T cell memory formation 128 . Emerging findings indicate that naturally occurring and in vitro-generated T SCM cells also exhibit the 'metabolic signature' of conventional memory cells 113, 137 . Recently, HSC and T cell stemness have been linked to decreased mitochondrial membrane potential (∆Ψm) 151 . Analogously, T SCM cells display lower ∆Ψm than other antigen-experienced T cell subsets 137, 151 . Whether T SCM cells maintain the fused mitochondrial networks with tight cristae organization seen in conventional memory T cells 152 remains to be determined. Future areas of research include the role of amino acids and a global characterization of the T SCM cell metabolome.
T SCM cell anatomical niches. Stem cell niches are instrumental in the regulation of stem-cell behavior and tissue homeostasis, guiding HSCs to either self-renew or differentiate 153 . Accumulating evidence underscores the crucial role of the bone marrow in sustaining the persistence of memory T cells [154] [155] [156] [157] . Whether the bone marrow similarly serves as a T SCM cell niche is a fundamental question. Alternatively, akin to naive T cells 158 , T SCM cells might rely on homeostatic cues provided by fibroblastic reticular cell niches within lymph nodes. Finally, the characterization of contact-dependent cross-talk, cytokine networks and metabolite constituents regulating T SCM cells in their niches remains to be addressed.
of existing pharmacological inhibitors of Wnt-β-catenin designed to target cancer stem cells 132 . Although such a strategy might be not entirely specific to the elimination of HIV-1-specific CD4 + T SCM cells, advances in nanotechnology might enable selective delivery of Wnt-β-catenin antagonists or short hairpin RNAs targeting key mediators of Wnt signaling to CD4 + T cells or virally infected cells via nanoparticles or aptamer-based targeting systems 133, 134 (Fig. 3) . Similar strategies are also conceivable for targeting HTLV-1-infected T SCM cells in the setting of ATL or to disrupt long-lasting reservoirs of autoreactive T SCM cells in autoimmune diseases. Additionally, recent advances in gene editing ex vivo might enable the design of CD4 + T SCM cells that are intrinsically resistant to HIV-1, through, for example, targeted deletion of the chemokine receptor CCR5, which is necessary for viral entry 135 , thus mimicking the CCR5∆32 mutation known to confer resistance to HIV-1 infection 136 (Fig. 3) . Such a population of long-lasting, HIV-1-resistant CD4 + T cells could be used in adoptive immunotherapy strategies to establish a durable cellular immune system that is no longer able to support HIV-1 infection and that might lead to drug-free remission of HIV-1 infection.
Concluding remarks
T SCM cells are rare, antigen-experienced T cells, probably generated directly from naive lymphocytes and endowed with long-term selfrenewal capacity and multipotency. Compelling evidence in mice, NHPs and humans points toward a scenario in which T SCM cells represent the apex of the memory T cell differentiation tree. Their longevity and their capacity to reconstitute the entire heterogeneity of the T cell memory compartment entail a double-edged-protective or pathogenic-role for T SCM cells in human diseases. Their increasingly recognized protective role in acute and chronic infections makes them optimal candidates for therapeutic exploitation in vaccination and adoptive T cell therapy against infectious diseases and cancer. Conversely, their relevance in the pathogenesis of autoimmunity, adult T cell leukemia and HIV-1 makes them an attractive target to tame for these pathological conditions. Several issues regarding T SCM cell biology remain to be addressed: characterization of their metabolic requirements, epigenetic and transcriptional programs and anatomical niches (Box 1) will guide innovative T SCM cell-based therapeutic interventions for human diseases.
